Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757188 | 1.00 | GPR119 (0.53) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL31605540 | 0.90 | GPR119 (0.53) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL20046465 | 0.89 | HRH3 (0.51) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL20076058 | 0.89 | GPR119 (0.47) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30893463 | 0.87 | GPR119 (0.52) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL23960996 | 0.87 | GPR119 (0.52) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24379281 | 0.86 | GPR119 (0.45) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL23572658 | 0.86 | GPR119 (0.45) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30054438 | 0.86 | GPR119 (0.45) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL20046424 | 0.85 | GPR119 (0.47) | GPR119CKS1BSKP1SKP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024097775-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116829524-A | Method for alkylating acidic functional groups | 中外制药株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022262782-A1 | GLUTARIMIDE-SUBSTITUTED ISOXAZOLE FUSED RING COMPOUND, AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2022149618-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| CN-113149981-B | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
| CN-113149981-A | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | GPR119 2743/4885CKS1B 361/4885SKP1 659/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | GPR119 4286/4885CKS1B 3002/4885SKP1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.